By Curtana Pharmaceuticals Designation for first-in-class OLIG2 inhibitor highlights the urgent need for new therapies in aggressive pediatric brain cancers and qualifies Curtana for a potential Priority Review Voucher upon FDA approval.
|
By Mark Massey Legacy Foundation Official Foundation Launch to Elevate Awareness for Pediatric Brain Cancer
|
By Curtana Pharmaceuticals Curtana Pharmaceuticals Announces New Data Confirming CT-179 Effectively Crosses Blood-Brain Barrier and Synergizes with Radiation in Pediatric Brain Cancers
|
By Curtana Pharmaceuticals Preclinical Study Reveals that CT-179 Remodels the Tumor Microenvironment – Turning "Cold" Tumors "Hot" – and Significantly Enhancing the Efficacy of Immune Checkpoint Inhibitors
|
By Curtana Pharmaceuticals Curtana Pharmaceuticals, a biotechnology company focused on improving outcomes for brain cancer patients, is proud to announce the publication of two pioneering studies in Nature Communications.
|
